Full Press Release Details
BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia.
BBIO
BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia
Key Takeaway: BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia
Price reaction · baseline $9.74 (2022-01-26 close) · hit after-hours · clean, no other BBIO news in the window
day 0 close
-8.1%
day 1
-7.2%
day 3 · peak
+11%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis